Viromed Medical AG, a medical technology company specializing in cold plasma technology, announced the immediate appointment of Prof. Dr. Michael A. Rubhausen to its Medical Advisory Board. The physicist, known for his work in modern spectroscopy and materials research, will bring scientific depth to the board, particularly in evaluating the intersection of material properties, spectroscopy, and cold plasma.
Uwe Perbandt, CEO of Viromed Medical AG, emphasized the strategic value of the appointment: “With Prof. Dr. Michael A. Rubhausen, we are gaining a proven expert in modern spectroscopy and materials research for our Medical Advisory Board. His expertise is intended to help us thoroughly evaluate scientific questions at the intersection of material properties, spectroscopy, and cold plasma, and support our further research work.” This move underscores Viromed's commitment to advancing its cold plasma technology through rigorous scientific validation and innovation.
Prof. Rubhausen heads the Optics Working Group at the Institute of Nanostructure and Solid-State Physics at Universität Hamburg and serves as the Institute’s Managing Director. He is also affiliated with the Center for Free-Electron Laser Science (CFEL). His research focuses on advanced spectroscopic methods, including Raman spectroscopy and ellipsometry, which he applies to study superconductors, quantum materials, and biological and inorganic samples at large-scale research facilities such as PETRA III and FLASH.
With over 180 publications and approximately 4,000 citations, Prof. Rubhausen has contributed to prestigious journals like Physical Review Letters, JACS, Angewandte Chemie, Nature Chemistry, Nature Physics, Cellular and Molecular Life Sciences, and Nature Communications. Additionally, he is developing AI-supported analysis workflows for complex datasets, a skill that could be pivotal for analyzing cold plasma interactions with biological materials.
The appointment comes as Viromed Medical, listed since October 2022, seeks to expand the medical applications of cold plasma technology. The company, through its subsidiary Viromed Medical GmbH, distributes innovative cold plasma products across the DACH region and beyond. By integrating cutting-edge spectroscopic expertise, Viromed aims to better understand how cold plasma affects materials at a fundamental level, potentially leading to more effective medical treatments.
Cold plasma, often described as ionized gas, has shown promise in wound healing, disinfection, and even cancer therapy. However, its mechanisms of action are not fully understood. Prof. Rubhausen’s background in spectroscopy could help elucidate these mechanisms, enabling Viromed to optimize their devices and validate their efficacy more robustly. His experience with large-scale research facilities may also open doors for collaborative studies that strengthen the scientific credibility of Viromed’s products.
“We are delighted to welcome Prof. Rubhausen to our advisory board,” added Perbandt. “His interdisciplinary approach and deep understanding of material properties will be invaluable as we continue to pioneer cold plasma technology in medicine.” The company’s focus on scientific rigor aligns with its goal to realize growth potential in the coming years, as it seeks to position cold plasma as a mainstream medical tool.
For more information about Viromed Medical AG, visit their official website at www.viromed-medical-ag.de.
